Open in interactive viewer → charts, metric popovers & call review

Hims & Hers Sells You a Pause: 100,000 Fewer Subscribers and a Membership That Eats Revenue

Revenue accelerated to +49%, but the weight-loss marketing was switched off on purpose, guidance came down, and a subscription accounting shift now defers $18 million a quarter.
HIMS · Earnings Call · 2026-11-09

The pause is the product

Hims & Hers just reported the strangest kind of strong quarter. Revenue rose 49% year over year to $890 million — a second consecutive quarter of acceleration — while the subscriber count fell by 100,000 sequentially to 2.8 million. Management did not dress it up. “Subscribers grew 13% year over year to 2.8 million, though declined sequentially by 100,000 net subscribers quarter over quarter as a result of measured marketing spend in our domestic weight loss specialty” — Yemi Okupe, Chief Financial Officer · 2026-11-09. In a business whose entire history has been a subscriber-acquisition flywheel, that is not a rounding error. It is a decision. The logic, as laid out, is that the weight-loss category was about to get structurally better in January and it was stupid to buy customers 45 days early. Lilly is joining Novo on the platform — Zepbound and Foundayo alongside Wegovy pen and pill, with Cagrisema queued — plus multi-month subscriptions and a broader broad assortment of form factors and price points. So the spend was throttled, and the Lilly deal is the thing they are asking you to underwrite. “At that point, we'll lean back into the marketing engines, and we would expect subscriber growth to recover and start to grow from there” — Yemi Okupe, Chief Financial Officer · 2026-11-09. Except the fourth quarter does not show that recovery. "We expect to continue to moderate domestic marketing investment in the U.S. within our weight loss specialty in the fourth quarter, which may lead to an additional quarter of subscriber count headwinds." Two consecutive quarters of shrinking subscriber count into a January launch that has to work.

These are very known, known things that have worked across categories. I think our perspective is in advance of January 1st, when we know that this category really explodes with demand, let's unlock those levers. Let's focus there. Let's not unnecessarily burn that cash and prepare in order to do this the right way 45 days from now.

Andrew Dudum, Chief Executive Officer · 2026-11-09
That is a coherent argument. It is also, functionally, a bet that the market will still be there in February.

Guidance cut, borrowed against next year

The bill arrived in the outlook. Full-year revenue was merely tightened to $3.13–3.15 billion, but the adjusted EBITDA range was cut to $257–277 million — attributed to aggressive strategic pricing and marketing in the UK and Germany plus the membership deferral. Q4 is guided to $70–90 million of adjusted EBITDA on $875–895 million of revenue, 9% at the midpoint. On the August call, an analyst was working off roughly “12% at the midpoint” — Glen Santangelo, Analyst · 2026-08-10 for the fourth quarter. Three points of margin, gone, in one quarter, in exchange for a promise. The gross-margin mechanics are real and not going away: branded GLP-1s and international carry structurally thinner economics than the old compounded book. Gross margin printed 57% in the quarter, down roughly seven points sequentially, and the reported series has now given back nearly twenty points from its 2024 peak. What used to be a software-like margin business is becoming a pharmaceutical distribution business with a subscription front end, and the market has not finished repricing that.

The quiet change: a membership that eats revenue

The most under-discussed line on the call was a $18 million revenue exclusion — weight-loss membership revenue that was received but deferred into Q4, with at least a $20 million full-year impact because December payments will not be recognized until January. That is the membership model arriving, and it changes the shape of the P&L rather than the size. Andrew Dudum had flagged it a quarter earlier as a someday thing: “this sets up very well for a natural membership offering for Hims & Hers, as you can imagine, coming out in the coming year or 2” — Andrew Dudum, Co-Founder and Chief Executive Officer · 2026-08-10. It has arrived faster than that, and it is already distorting quarterly revenue optics in both directions — a headwind now, a pull-forward later. The same is true of the marketing investment story: marketing fell seven points as a percentage of revenue to 28% while revenue accelerated. That is genuine leverage, or it is a quarter where you simply didn't spend. The next two quarters will tell you which.

What they stopped talking about

Three themes that dominated recent calls have gone quiet. First, labs. In November 2025 the promise was explicit: “we will be launching the whole body lab testing on the platform very soon before the year-end” — Andrew Dudum, Co-Founder and CEO · 2025-11-03, with a longevity specialty promised for 2026. On this call, lab testing survives only as a phrase inside "a million square feet of pharmacy, lab, and compounding infrastructure." The proactive-care narrative that was going to reposition the brand has been subordinated to metabolic health and peptides. Second, Eucalyptus — the acquisition that powered international revenue to $233 million, more than 4x year over year, with roughly $135 million of it from Eucalyptus itself — is being dissolved into the parent. Hers launched in Australia and Germany, HIMS in Germany and Australia, and the consolidation is explicitly expected to cost subscribers near term. The brand that was the international story a year ago is now just a platform. Third, peptides. The peptide offering lands this month with sermorelin, glutathione and NAD+, with BPC-157 and TB-500 gated behind rulemaking. Management had been emphatic that they would not front-run the FDA: “Our operating model today is that we are waiting on full and final rule making from the FDA” — Andrew Dudum, Co-Founder and Chief Executive Officer · 2026-08-10. They still are, for the six PCAC peptides — but the wellness tier is going to market into an open comment period, and the regulatory answer is now, in the CEO's own words, “we're in a comment period where the FDA has put out the proposed ruling from HHS” — Andrew Dudum, Chief Executive Officer · 2026-11-09. That is a modest but real softening of a stance they spent three quarters advertising. Peptide revenue is guided to be immaterial this quarter, so the option is free — for now.

The tape has already voted

The stock is down 40% in ninety days and 66.6% from its February 2025 peak of $68.74, leaving a $5.2 billion market cap. At about 3.1x revenue, versus 14.8x at the 2021 peak, the market is not paying for the January reset; it is discounting it. Meanwhile the operating margin sits at -12.9% and liabilities are now 91% of assets. The global tape is a partial defense: GLP-1 growth names were among the better 90-day advancers in the market-wide screen, and weight-management adjacency kept showing up across reporters — WW's GLP-1 program, IFF's GLP-1 user cohort, G1A's oral GLP-1. The category is not dead. Hims & Hers' problem is idiosyncratic: it is choosing to shrink its subscriber base, in the one category that is working, to buy an assortment advantage it has not yet proven it can monetize. Bull case is Canada — monthly orders up more than 50% after generics arrived, margins improving. Bear case is that January's demand peak arrives before the machine is turned back on. The AI-native experience now reaches 70% of weight-loss subscribers and 4x's messaging, which is a genuine retention lever. Whether it is enough to offset a deliberate 100,000-subscriber hole is the only question that matters for the next two prints.